A Blog by Jonathan Low


Oct 23, 2020

Why Covid Antibody Treatments,, Though Promising, Will Be In Short Supply

Only two companies manufacture them and they do not have the capacity yet to provide the doses required, given that 60,000 Americans are testing positive every day. 

As with vaccines, distribution is complicated, especially since the antibodies have to be administered intravenously in a hospital or doctor's office, further limiting access. JL

Katie Thomas reports in the New York Times:

Antibodies might be used both as a treatment for those who are sick and to prevent infection in people who have been exposed. The treatments could serve as a bridge to a vaccine. (But) 60,000 Americans are testing positive for the coronavirus every day, yet the company that provided the president’s antibody treatment, Regeneron, will have only 50,000 doses initially. Eli Lilly will have 100,000 doses at first. The therapies are given intravenously, requiring an infected person to visit a medical clinic or a hospital. People who are older and obese will benefit the most from the treatment.

Nearly two weeks ago, President Trump told Americans that they would soon be getting an antibody treatment that he had promoted, without evidence, as a “cure” for the coronavirus. This weekend, as the country braced for another major wave of coronavirus infections, Mr. Trump’s health secretary promised such therapies were just around the corner.

But these statements are misleading, at best. Even if the drugs are proven to work — still a big if — there’s little chance that they will soon be widely available. A smooth distribution of the antibody treatments will be dependent on the very same factors that have so far bedeviled the country’s response to Covid-19: fast and plentiful testing, coordination between state and federal officials, and equitable access to health care.

Supply will be extremely limited at first, even though the pool of patients who might benefit is vast, raising messy questions about who should be first in line for treatment. The drugs are believed to work best in people who have recently been infected and are not yet very sick.

“It is just a setup for everything challenging about the pandemic that we’ve had until now, which is confusion, inequity, delays, reliance on testing,” said Dr. Walid Gellad, the director of the Center for Pharmaceutical Policy and Prescribing at the University of Pittsburgh. The therapies are promising, he said, but with “everything that’s gone wrong, it’s going to accentuate the problems.”

Roughly 60,000 Americans are testing positive for the coronavirus every day, yet the company that provided the president’s antibody treatment, Regeneron, has said it will have only 50,000 doses initially. Eli Lilly, which is developing a similar product, has said it will have 100,000 doses at first. Regeneron will eventually have 300,000 doses, and Eli Lilly will have up to one million before the end of the year. Both companies have applied to the Food and Drug Administration for emergency authorization of their products.

Administering the treatment is not as simple as handing out a bottle of pills. The therapies are given intravenously, requiring an infected person to visit a medical clinic or a hospital.

That’s assuming that the distribution will go smoothly. Officials with Operation Warp Speed, the government effort to speed treatments and vaccines to market, recently told reporters that the federal government would hand over to states the job of allocating the initial doses of Regeneron drugs. But those state agencies are overwhelmed from handling the current influx of new cases, as well as from planning for the distribution of coronavirus tests and future vaccines, and have not yet made detailed plans for deciding how to allocate the antibody treatments to hospitals and clinics.

“We really have a lot going on, and this has not been front and center,” said Dr. Marcus Plescia, the chief medical officer of the Association of State and Territorial Health Officials.

Even some company executives have acknowledged that the country may not yet be up to the challenge. Dr. George Yancopoulos, the president and chief scientific officer of Regeneron, said in a recent call with investors and reporters that communities would need to have rapid testing and contact tracing in place to identify the best candidates for the treatments.

“We, as a society, are literally trying to fly a plane while we’re trying to build it here,” he said.

Early data about the therapies have shown that they help clear the virus in people who have recently been infected, and that they may help prevent hospitalizations. In another positive sign, the F.D.A. recently approved an Ebola treatment made by Regeneron that uses the same technology.

Eli Lilly and Regeneron have said the antibodies might be used both as a treatment for those who are sick and to prevent infection in people who have been exposed. The treatments could serve as a bridge to a vaccine, protecting high-risk groups like nursing home residents and the workers who care for them.

Still, it’s unclear when the F.D.A. will give a green light to emergency authorization. Regulators must review a mountain of data and decide which groups might benefit the most. Last week, a government-backed clinical trial testing the Eli Lilly therapy in hospitalized patients was paused for unspecified safety reasons, and it will not restart until at least Oct. 26.

If an emergency authorization does come through, Regeneron’s first 300,000 doses will go to the federal government, thanks to an advance purchase agreement. Those initial doses will be free of charge to Americans.

Eli Lilly has not made a similar deal, but at a recent news conference, the chief executive, David A. Ricks, said “conversations are ongoing” with Operation Warp Speed.

There are also likely to be questions about whether wealthy or well-connected patients will be able to unfairly move to the front of the line. Few would argue that the president should not have been given emergency access to Regeneron’s treatment, given the national security stakes. But it’s unclear what criteria Eli Lilly used when the drugmaker cleared its treatment for Chris Christie, the former governor of New Jersey. (A spokeswoman for Eli Lilly declined to discuss specific cases, citing patient privacy, but she said the company approves such treatments on a case-by-case basis in “exceptional circumstances.”)

Dr. Douglas B. White, a medical ethicist and professor of critical care medicine at the University of Pittsburgh School of Medicine, said he hoped hospitals would apply the lessons they had learned when another experimental Covid-19 drug, remdesivir, was initially scarce. Then, too, the federal government asked states to take responsibility for how the drug was allocated.

Dr. White wrote guidelines that were adopted by Pennsylvania that recommended giving priority to people from economically disadvantaged communities, who are at higher risk of dying from Covid-19. The same rules should apply to the antibody treatments, if they are in short supply, he said.

“There needs to be clear guidelines, and there needs to be efforts to mitigate the inequitable outcomes across groups in society,” he said.

Dr. Plescia, of the state health officials group, said he believed that most states had worked out the kinks that occurred with remdesivir. Now, he said, “I think there’s a distribution chain in place that could be adapted to this.”

The antibody treatment will present new challenges.

Eli Lilly has said that people who are older and obese are at higher risk for poor outcomes from Covid-19 and will benefit the most from the treatment. Regeneron has said that people whose bodies are not producing antibodies appear to be the best candidates.

In early trial data released by Eli Lilly, 5.8 percent of people who received a placebo were hospitalized or visited an emergency room for Covid-19, compared with 0.9 percent of people in the group that received the antibody treatment. Figuring out who will benefit the most is an enormous challenge, because most people will recover on their own.

Geoffrey Porges, a pharmaceutical analyst with SVB Leerink, an investment bank, said that means that 100 patients would need to be treated to prevent about five from going to the hospital. “That’s expensive and complicated, and you don’t know who the five are that would have gone to the hospital,” he said.

And because the treatments will be given to newly infected people, doctors will need a rapid turnaround in testing to quickly identify patients.

In Regeneron’s case, an antibody test may also be needed to identify patients whose immune systems are not responding. Dr. Yancopoulos acknowledged that such easy and fast tests were not yet widely available, and said that Regeneron was working with Roche to develop tests that could help doctors identify the right patients. In a statement, Roche said it was identifying which of its tests could help in “triaging” patients.

Mr. Ricks, the Eli Lilly chief executive, said his company took testing obstacles into account when it decided to classify high-risk patients based on age and weight. “In a practical clinical setting, it is something that could be applied immediately,” Mr. Ricks said on the recent investor call.

Even after the right patients have been identified, more hurdles await. Patients need to be quickly sent to a clinic or hospital that can administer the treatment, and kept separate from others who are not infected. They will need assistance from medical personnel in protective gear who can insert an intravenous line and monitor them while they are being infused with the drug.

If the antibody treatments prove effective, they are expected to become more widely available by early next year. Regeneron has said it will be able to produce about 250,000 doses a month in partnership with Roche. Eli Lilly has said it will also be able to ramp up production. Another company, AstraZeneca, is also developing an antibody treatment that is earlier in its development, and it has a deal with the federal government to supply up to 100,000 doses by the end of December.

In the meantime, some doctors on the front lines say they are eager for any new tool to keep people out of the hospital.

Dr. Manar Alshahrouri is a critical care doctor in Green Bay, Wis., one of many cities in the Upper Midwest where infections are surging. The intensive care units at the two hospitals in which he works are nearly full, he said. And there’s little to give patients who are newly sick with Covid-19 to prevent them from winding up there. “We don’t have, as of now, anything that is effective,” Dr. Alshahrouri said. “We simply do not.”

But he cautioned that hope for a miracle cure should not be used as a crutch, and it should not replace preventive measures like wearing masks.

Keeping people out of the hospital is “a great endpoint for us as clinicians, but it is not a substitute for far more effective measures,” he said. “If you have a flood in your basement, the answer is not more towels. The answer is to turn off the water.”


Robert Earl said...

[⏱️ 2min Read]
📁 Hiring a professional hacker has been one of the world's most technical valued navigating information.
•MOBILE PHONE HACKS.(Catching A Cheating Spouse).
High prolific information and Priviledges comes rare as it has been understood that what people do not see, they will never know. The affirmative ability to convey a profitable information Systematically is the majoy factor to success.
Welcome to the Global KOS hacking agency where every request on hacking related issues are fixed within a short period of time.
When you wonder “which hacking company should I hire, the first aspect that should concern you is Sincerity. Secondly, Rapid response. Clearly, you want to embark for services that povides swift response. With our astonishing Hackers, you will be glad to find out that our services Implies precision and action.
This post is definitely for those who are willing to turn their lives around for the better, either financial-wise, relationship-wise or businesses.
The manual Operation of this hackers is to potentially deploy a distinguished hacking techniques to penetrating computers.
If your shoe fits in any of the services below, you will be assigned to a designated professional hacker who is systematically known for operating on a dark web V-link protocol.
Providing value added services to clients as a hacker has been our sustaining goal.
Are you faced with cyber challenges like
💰Recovery of lost funds:✅(BITCOIN INVESTMENTS, BINARY OPTIONS, LOAN AND TRADING FOREX WITH FORGERY BROKERS.) 🖥️I would try my possible best to shortly explain this in particular.
This shocking study points to one harsh reality we all face today. It saddens our mind when client expresses annoyance or dissatisfaction of unethical behaviours of scammers. We have striven to make tenacious efforts to help those who are victims of this flees get off their traumatic feeling of loss. The cyber security technique used to retrieving back the victims stolen funds is the application of a diverse intercall XX breacher software enables you track the data location of a scammer. Extracting every informations on the con database. Every information required by the Global KOS would be used to tracking every transaction, time and location of the scammer. This is acheived using the systematic courier tracking base method•
However, there are secret cyber infiltrators called brokers and doom. The particular system used by this scammers permeates them to manupulate targets digital trading system or monetary fund based accounts. Strictly using a dark web rob to diverting successful trades into a negative outcome. This process bends to thier advantage while investors results to losing massive amount of money. An act of gaining access to an organization or databased system to cause damages. We have worked so hard to ensure our services gives you a 100% trading success to recover all your losses•
📲 HACKING A MOBILE PHONE:.✅ Do you think you are being cheated on? Curious to know what your lover is up to online? This type of hack helps you track every movement of your cheater as we are bent on helping you gain full remote access into the cheater's mobile phone using a Trojan breach cracking system to penetrate their social media platforms like Facebook, whatsapp, snapchat etc.
The company is large enough to provide comprehensive range of services such as•
Our strength is based on the ability to help fix cyber problems by bringing together active cyber hacking professionals in the GlobalkOS to work with.
✉️Email: theglobalkos@gmail.com
®Global KOS™

Post a Comment